NCT04675996 is a Phase 1 clinical trial of INT-1B3 in Solid Tumor, sponsored by InteRNA.

Who is sponsoring NCT04675996?

NCT04675996 is sponsored by InteRNA.

What drugs are being tested in NCT04675996?

Interventions in NCT04675996: INT-1B3.

What condition does NCT04675996 study?

NCT04675996 studies Solid Tumor.

Is NCT04675996 still recruiting?

NCT04675996 is currently terminated. Last updated 8 February 2024.

Last reviewed 2024-02-08 · How we verify

NCT04675996

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

First-in-Human Study of INT-1B3 in Patients With Advanced Solid Tumors

Terminated Phase 1 Last updated 8 February 2024

What this trial tests

Phase 1 trial testing INT-1B3 in Solid Tumor in 25 participants. Terminated before completion.

Timeline

18 December 2020

Primary endpoint
24 March 2023

24 March 2023

Quick facts

Lead sponsor	InteRNA
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	18 December 2020
Primary completion	24 March 2023
Estimated completion	24 March 2023
Sites	4 locations across Belgium, Netherlands

Drugs / interventions tested

INT-1B3 — full drug profile →

Conditions studied

Solid Tumor — all drugs for Solid Tumor →

Sponsor

InteRNA — full company profile →

Who can join

18 and older, any sex, with Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a 2 part, multi-center, open-label, First-in-Human clinical study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of INT-1B3 in the treatment of patients with advanced solid tumors.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies.
Kim T, Croce CM. · · 2023 · cited 270× · PMID 37430087 · DOI 10.1038/s12276-023-01050-9
Trials and Tribulations of MicroRNA Therapeutics.
Seyhan AA. · · 2024 · cited 229× · PMID 38338746 · DOI 10.3390/ijms25031469
Non-viral vectors for RNA delivery.
Yan Y, Liu XY, Lu A, Wang XY, et al · · 2022 · cited 213× · PMID 35016918 · DOI 10.1016/j.jconrel.2022.01.008
Recent Advances in Oligonucleotide Therapeutics in Oncology.
Xiong H, Veedu RN, Diermeier SD. · · 2021 · cited 132× · PMID 33804856 · DOI 10.3390/ijms22073295
Epigenetics-targeted drugs: current paradigms and future challenges.
Dai W, Qiao X, Fang Y, Guo R, et al · · 2024 · cited 131× · PMID 39592582 · DOI 10.1038/s41392-024-02039-0
Nanoparticle delivery of miR-21-3p sensitizes melanoma to anti-PD-1 immunotherapy by promoting ferroptosis.
Guo W, Wu Z, Chen J, Guo S, et al · · 2022 · cited 100× · PMID 35738798 · DOI 10.1136/jitc-2021-004381
Cancer nanomedicine: a review of nano-therapeutics and challenges ahead.
Nirmala MJ, Kizhuveetil U, Johnson A, G B, et al · · 2023 · cited 86× · PMID 36926304 · DOI 10.1039/d2ra07863e
MicroRNA in cancer therapy: breakthroughs and challenges in early clinical applications.
Di Martino MT, Tagliaferri P, Tassone P. · · 2025 · cited 80× · PMID 40259326 · DOI 10.1186/s13046-025-03391-x

Verify or expand the search:

Other recruiting trials for Solid Tumor

Currently open trials in the same condition.

NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04675996 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by InteRNA
Last refreshed: 8 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04675996.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing